Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

(2013) M. Pratcorona et al.   BLOOD

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

(2013) V. I. Gaidzik et al.   BLOOD

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

(2013) N. Shayegi et al.   BLOOD

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

(2013) E. Jourdan et al.   BLOOD

MicroRNAs in myeloid malignancies

(2013) Jane E. A. Gordon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy

(2013) Naval Daver et al.   Clinical Lymphoma Myeloma & Leukemia

Gene mutations of acute myeloid leukemia in the genome era

(2013) Tomoki Naoe et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia:miR-155Upregulation Independently Identifies High-Risk Patients

(2013) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study

(2013) Zejuan Li et al.   JOURNAL OF CLINICAL ONCOLOGY

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

(2013) Monique Terwijn et al.   JOURNAL OF CLINICAL ONCOLOGY

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

(2013) C Allen et al.   LEUKEMIA

CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)

(2013) Noriyoshi Iriyama et al.   LEUKEMIA RESEARCH

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

(2012) F. Schneider et al.   BLOOD

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

(2012) M. R. Loken et al.   BLOOD

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

(2012) A. F. T. Ribeiro et al.   BLOOD

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

(2012) Z. Li et al.   BLOOD

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

(2012) M. Gonen et al.   BLOOD

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

(2012) R. Liersch et al.   BLOOD

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

(2012) P. Paschka et al.   BLOOD

A novel hierarchical prognostic model of AML solely based on molecular mutations

(2012) V. Grossmann et al.   BLOOD

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

(2012) A.-K. Eisfeld et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

DNA methylation analysis ofALOX12andGSTM1in acute myeloid leukaemia identifies prognostically significant groups

(2012) Robert S. Ohgami et al.   BRITISH JOURNAL OF HAEMATOLOGY

Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia

(2012) Martha Arellano et al.   CANCER

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

(2012) B. Deschler et al.   HAEMATOLOGICA

Age-Related Prognostic Impact of Different Types ofDNMT3AMutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

(2012) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group

(2012) Verena I. Gaidzik et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients

(2012) Sadudee Chotirat et al.   Journal of Hematology & Oncology

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

(2012) A Renneville et al.   LEUKEMIA

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

(2012) S Schnittger et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

Potential application ofIDH1andIDH2mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis

(2012) Kuang-Guo Zhou et al.   LEUKEMIA & LYMPHOMA

Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group

(2012) J. Nomdedéu et al.   LEUKEMIA RESEARCH

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

(2011) S. Kayser et al.   BLOOD

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

(2011) Y. Shen et al.   BLOOD

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

(2011) S. Deneberg et al.   BLOOD

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

(2011) M. B. Treppendahl et al.   BLOOD

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers

(2011) V. Rockova et al.   BLOOD

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype

(2011) F. Damm et al.   BLOOD

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

(2011) C. L. Green et al.   BLOOD

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications

(2011) H.-A. Hou et al.   BLOOD

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

(2011) K. H. Metzeler et al.   BLOOD

Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene

(2011) S. Agrawal-Singh et al.   BLOOD

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

(2011) F. G. Rucker et al.   BLOOD

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

(2011) W.-C. Chou et al.   BLOOD

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin

(2011) Farhad Ravandi et al.   CANCER

Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia

(2011) Jana Marková et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

(2011) M. Stelljes et al.   HAEMATOLOGICA

Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission

(2011) M. Yanada et al.   HAEMATOLOGICA

Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD

(2011) H. J. M. de Jonge et al.   HAEMATOLOGICA

Prognostic Importance of Histone Methyltransferase MLL5 Expression in Acute Myeloid Leukemia

(2011) Frederik Damm et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia

(2011) Felicitas Thol et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

(2011) Jan Krönke et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2011) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial

(2011) Markus Pfirrmann et al.   LANCET ONCOLOGY

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

(2011) S Schnittger et al.   LEUKEMIA

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

(2011) K H Metzeler et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

WT1 overexpression at diagnosis may predict favorable outcome in patients withde novonon-M3 acute myeloid leukemia

(2011) Maurizio Miglino et al.   LEUKEMIA & LYMPHOMA

Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients

(2011) Yiqun Zhang et al.   LEUKEMIA RESEARCH

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

(2011) Xiao-Jing Yan et al.   NATURE GENETICS

Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies

(2010) Britta Will et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

(2010) S. Schnittger et al.   BLOOD

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

(2010) S. Abbas et al.   BLOOD

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

(2010) C. L. Green et al.   BLOOD

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

(2010) F. Thol et al.   BLOOD

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation

(2010) W. C. Chou et al.   BLOOD

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. P. Whitman et al.   BLOOD

Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations

(2010) W.-C. Chou et al.   BLOOD

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia

(2010) C. Muller-Tidow et al.   BLOOD

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

(2010) S. Kayser et al.   BLOOD

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

(2010) S. Schnittger et al.   BLOOD

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

(2010) F. Buccisano et al.   BLOOD

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

(2010) C. Rollig et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

(2010) N. H. Thoennissen et al.   BLOOD

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

(2010) Maria E. Figueroa et al.   CANCER CELL

Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia

(2010) G. Gianfaldoni et al.   HAEMATOLOGICA

Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group

(2010) Nicolas Boissel et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor

(2010) Katharina Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of Expression of a Single MicroRNA,miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Sebastian Schwind et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance ofCEBPAMutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of DoubleCEBPAMutations and the Interaction WithFLT3andNPM1Mutations

(2010) Claire L. Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A

(2010) Richard F. Schlenk et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

(2010) Utz Krug et al.   LANCET

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

(2010) V H J van der Velden et al.   LEUKEMIA

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study

(2010) P A Ho et al.   LEUKEMIA

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia

(2010) S Deneberg et al.   LEUKEMIA

CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia

(2010) T-C Lin et al.   LEUKEMIA

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

(2010) W-C Chou et al.   LEUKEMIA

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: A systematic review

(2010) Amer Beitinjaneh et al.   LEUKEMIA RESEARCH

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

(2010) Y. Saito et al.   Science Translational Medicine

Prognostic impact ofWT1mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

(2009) Verena Ingeborg Gaidzik et al.   BLOOD

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia

(2009) R. Tang et al.   BLOOD

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD

Quantitative DNA methylation predicts survival in adult acute myeloid leukemia

(2009) L. Bullinger et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations

(2009) J.-L. Tang et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

(2009) A. K. Burnett et al.   BLOOD

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

(2009) Monique Terwijn et al.   EUROPEAN JOURNAL OF CANCER

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients

(2009) Massimo Breccia et al.   HEMATOLOGICAL ONCOLOGY

CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients

(2009) Elisabet Björklund et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

(2009) John Koreth et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prognostic Factors in Adult Patients up to 60 Years Old With Acute Myeloid Leukemia and Translocations of Chromosome Band 11q23: Individual Patient Data–Based Meta-Analysis of the German Acute Myeloid Leukemia Intergroup

(2009) Jürgen Krauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

Single Nucleotide Polymorphism in the Mutational Hotspot of WT1 Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia

(2009) Frederik Damm et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

(2009) Heiko Becker et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome

(2009) Annika Dufour et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

Monitoring minimal residual disease in acute myeloid leukaemia withNPM1mutations by quantitative PCR: clonal evolution is a limiting factor

(2008) Christina Papadaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Prognostic Significance of Serum  2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

(2008) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

(2008) R. F. Schlenk et al.   HAEMATOLOGICA

Mutation of the Wilms’ Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party

(2008) Priya Virappane et al.   JOURNAL OF CLINICAL ONCOLOGY

Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2008) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

(2008) Dimitri A. Breems et al.   JOURNAL OF CLINICAL ONCOLOGY

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

(2008) Andreas Neubauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

(2008) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study

(2008) F Lacombe et al.   LEUKEMIA

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

(2008) C Haferlach et al.   LEUKEMIA

Cytogenetically Normal Acute Myeloid Leukemia

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Absolute lymphocyte count is a novel prognostic indicator in ALL and AML

(2007) Guillermo De Angulo et al.   CANCER

Significance of age in acute myeloid leukemia patients younger than 30 years

(2007) Ursula Creutzig et al.   CANCER